IMMP (IMMP) Stock Price & Analysis
IMMP (IMMP) fell 2.01% to USD 0.38 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
IMMP last closed at USD 0.39; the session ranged USD 0.38–0.4 on volume of 226,624 shares. Market capitalization is $56.66M, with a 52-week range of USD 0.29–3.53 (NGM). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 0.38 |
|---|---|
| Change | ▼ 2.01% (down) |
| Previous Close | USD 0.39 |
| Open | USD 0.39 |
| Day Range | USD 0.38 – 0.4 |
| 52-Week Range | USD 0.29 – 3.53 |
| Volume | 226,624 shares |
| Market Cap | $56.66M |
| Exchange | NGM |
Technical Analysis (IMMP)
Nexqual's technical model rates IMMP "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.45 (neutral) |
| vs SMA50 | Below (USD 0.42) |
| MACD | -0.01 (negative) |
Analyst Ratings (IMMP)
Wall Street analysts rate IMMP "None" based on 1 analysts, with a mean price target of USD 1.5 (range USD 1.5–1.5), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 1.5 |
| High Target | USD 1.5 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (IMMP)
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (IMMP)
| Total Revenue | $7.92M |
|---|---|
| Revenue Growth (YoY) | +91.50% |
| Gross Margin | +0.00% |
| Operating Margin | -763.71% |
| Profit Margin | +0.00% |
| ROE | -61.85% |
| Debt / Equity | 1.22 |
| Current Ratio | 2.97 |
| Total Cash | $99.13M |
| Total Debt | $1.21M |
| Free Cash Flow | $-35.68M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (IMMP)
Nexqual rates IMMP's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Strong — Revenue +32% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $99M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$36M, burning cash |
| Efficiency | Critical — ROE -62%, ROA -32.1% |
Ownership (IMMP)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +2.43% |
| Shares Outstanding | 147.37M |
| Float | 143.03M |
| Short % of Float | +2.72% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (IMMP)
IMMP is led by Marc Voigt (age 52), CEO, MD, CFO, Chief Business Officer & Executive Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| CEO, MD, CFO, Chief Business Officer & Executive Director | Marc Voigt (age 52) |
|---|---|
| COO, General Counsel & Joint Company Secretary | Deanne Miller LLB (age 48) |
| Chief Scientific Officer & Executive Director | Frederic Triebel (age 70) |
Major Backers & Investors (IMMP)
Notable institutional backers of IMMP include UBS Group AG, Meridian Wealth Management, LLC, Two Sigma Investments, LP, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.51% |
| Meridian Wealth Management, LLC | 0.31% |
| Two Sigma Investments, LP | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.04% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLSI | Greenwich LifeSciences, Inc. | USD 12.98 | ▼ 2.19% |
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| ATHE | Alterity Therapeutics Limited | USD 4.54 | ▼ 3.4% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.14 | ▼ 1.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.